3 Polish doctors convicted in 2021 death of pregnant woman
The death from sepsis of the woman known as Iza at a hospital in southern Poland in her 22nd week of pregnancy led to huge street protests against the country's restrictive anti-abortion law. Activists blamed her death on doctors' choice to 'wait and see' rather than immediately carry out an abortion because of the Poland's near-ban on the procedure.
Two of the doctors were sentenced to more than a year in prison without parole and the third received a two-year suspended sentence, PAP reported Thursday. They can appeal the decision.
The charges, filed in 2022, were of exposing the patient to the danger of loss of life. Two of the doctors also were charged with unintentionally causing the patient's death.
'As a result of the team's activity and the failure to act, the patient has died,' Agnieszka Wichary, spokesperson for the prosecutors' office in Katowice, said in a statement at the time.
Poland, a mostly Catholic country, passed a strict law in 1993 that banned abortions except when the pregnancy resulted from rape or incest, when the woman's life or health is at risk, or when the fetus had congenital deformities.
But the Constitutional Tribunal, under the influence of Poland's conservative ruling party, ruled in 2020 that abortions for congenital defects were not constitutional, even if the fetus has no chance of survival. That sparked huge street protests.
Activists said Iza was the first to die from the further tightening of the restrictive law. The woman left behind a husband and a daughter.
In practice, activists say, many women have abortions on their own with pills obtained from abroad.
The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade
Key Points Pfizer and Novo Nordisk have underperformed the market over the past year. But both should remain major players in important areas within the pharma industry. Investors could see the two drugmakers' shares beat the market over the next decade. 10 stocks we like better than Pfizer › Pharmaceutical giants Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) have lagged the market over the past year, although Pfizer's poor performance dates back much further. Though these companies have encountered challenges, there are good reasons to be bullish on their long-term prospects. Pfizer could become an even bigger player in the oncology market (the largest therapeutic area in the industry by sales) over the next decade, while Novo Nordisk will be a major player in diabetes and the fast-growing weight management space. Both could produce excellent results along the way. Here's the rundown. 1. Pfizer Pfizer's financial results haven't been great in recent years. To make matters worse, the company will face important patent cliffs by the end of the decade. One of them will be for Eliquis, an anticoagulant that is still one of its best-selling medicines. However, Pfizer has prepared for that eventuality. The company made several acquisitions and licensing deals that significantly boosted its pipeline, especially in oncology. Pfizer spent $43 billion to acquire Seagen, a smaller cancer specialist whose lineup and pipeline were impressive for a company of its size. With the financial and strategic backing of the larger company, it should yield even more key approvals in the field in the coming years. Pfizer also recently made an up-front payment of $1.25 billion to China-based 3SBio for the rights to SSGJ-707, an investigational bispecific antibody, a portion of the oncology market that's gaining traction these days. 3SBio will be eligible for commercial and regulatory milestone payments of up to $4.8 billion, not including royalties. These moves should eventually pay off for Pfizer and strengthen its position in oncology. The drugmaker plans to have eight blockbuster cancer medicines on the market by 2030, up from its current five, while doubling its reach from the current 1 million patients it serves. Of course, Pfizer isn't just a cancer play. The company's extensive pipeline should enable it to launch products in other areas and ultimately get back on track. While its shares have been lagging the market significantly, that could change in the next decade as financial results rebound thanks to its innovative efforts. Pfizer's shares look especially attractive when considering its valuation. Its forward price-to-earnings (P/E) ratio is 8.7, much lower than the healthcare sector 's 15.8. From their current levels, Pfizer's shares could go on to generate excellent returns through 2035. 2. Novo Nordisk Novo Nordisk pioneered the market for weight management medicines. However, Eli Lilly seems to have taken the lead in that field, at least for now. Novo Nordisk has faced some clinical setbacks, leading to a poor performance over the trailing-12-month period. Can the company rebound and perform well in the next decade? In my view, it can, and the market may be significantly undervaluing its potential. Its sales of Wegovy, one of the top-selling anti-obesity medications, continue to grow rapidly. Novo Nordisk recently requested approval from the U.S. Food and Drug Administration for oral semaglutide (the active ingredient in Wegovy). That's good for patients who want a non-injected option, and helps counter Lilly's up-and-coming oral GLP-1 medicine, orforglipron. Elsewhere, Novo Nordisk recently started phase 3 studies for amycretin, a next-gen weight loss candidate. Amycretin is being investigated in both oral and subcutaneous formulations, and both are currently in late-stage clinical trials. The company also enhanced its pipeline through licensing deals, including one with United Biotechnology, a subsidiary of the China-based company United Laboratories International Holdings, for UBT251. This potential anti-obesity medicine mimics the actions of three gut hormones: GLP-1, GIP, and glucagon. The transaction cost Novo Nordisk an up-front payment of $200 million and up to $1.8 billion in milestone payments. Thanks to all these developments, Novo Nordisk should remain a leader in weight management in the next decade. Even though competition is mounting, no drugmaker not named Eli Lilly has a lineup or a pipeline as deep as Novo Nordisk's. Furthermore, the Denmark-based pharmaceutical leader will also continue to dominate the diabetes market, as it has done for decades. Novo Nordisk generates consistent revenue and earnings that typically grow faster than those of similarly-sized peers. Yet the stock's forward P/E is 16.7, which is slightly above the industry average. In my view, that's a bargain for a company that generates better-than-average results and has a deep pipeline in a fast-growing area -- not to mention two of the world's top 20 best-selling drugs, in Wegovy and Ozempic. For investors willing to stay the course, Novo Nordisk's future still looks incredibly bright. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
CBC
2 days ago
- CBC
Canadian woman dies after falling ill at Belgium's Tomorrowland music festival
A spokesperson for the Tomorrowland music festival says a Canadian woman has died after attending the large gathering in Belgium. Debby Wilmsen said in an emailed statement that a 35-year-old Canadian woman fell ill at the festival on Friday. She said the woman was given first aid and then taken to Antwerp University Hospital, but festival organizers were told Saturday morning that the woman had died. Wilmsen said the Antwerp public prosecutor's office is investigating the cause of death. The office did not respond to requests for information on the woman. Global Affairs Canada said it is aware of reports that a Canadian woman has died in Belgium but said it would not release information due to privacy considerations. Spokesperson Sabrina Williams said Global Affairs Canada is in contact with local authorities. A massive fire engulfed the main stage two days before the annual music festival began on Friday in the town of Boom, north of Brussels. Tomorrowland draws tens of thousands of visitors from around Europe and runs across two weekends, ending on July 27.
CTV News
3 days ago
- CTV News
3 Polish doctors convicted in 2021 death of pregnant woman
WARSAW, Poland — Three Polish doctors were convicted for their roles in the 2021 death of a 30-year-old pregnant woman that sparked massive protests, Polish news agency PAP reported. The death from sepsis of the woman known as Iza at a hospital in southern Poland in her 22nd week of pregnancy led to huge street protests against the country's restrictive anti-abortion law. Activists blamed her death on doctors' choice to 'wait and see' rather than immediately carry out an abortion because of the Poland's near-ban on the procedure. Two of the doctors were sentenced to more than a year in prison without parole and the third received a two-year suspended sentence, PAP reported Thursday. They can appeal the decision. The charges, filed in 2022, were of exposing the patient to the danger of loss of life. Two of the doctors also were charged with unintentionally causing the patient's death. 'As a result of the team's activity and the failure to act, the patient has died,' Agnieszka Wichary, spokesperson for the prosecutors' office in Katowice, said in a statement at the time. Poland, a mostly Catholic country, passed a strict law in 1993 that banned abortions except when the pregnancy resulted from rape or incest, when the woman's life or health is at risk, or when the fetus had congenital deformities. But the Constitutional Tribunal, under the influence of Poland's conservative ruling party, ruled in 2020 that abortions for congenital defects were not constitutional, even if the fetus has no chance of survival. That sparked huge street protests. Activists said Iza was the first to die from the further tightening of the restrictive law. The woman left behind a husband and a daughter. In practice, activists say, many women have abortions on their own with pills obtained from abroad. The Associated Press
